Infliximab and adalimumab have been shown to be largely equivalent in a real world cohort of biologic-naive patients with Crohn’s disease. A Canadian study of 220 adults found similar rates of clinical remission at 12 months (63.8 v 76.3%) and extending out to five years. Corticosteroid-free remission was also equivalent between the treatment groups (54.1 ...
‘Surprising’ evidence shows anti-TNFs on a par
By Mardi Chapman
23 Feb 2018